Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia

[1]  T. Haferlach,et al.  Molecular genetic characterization of myeloid/lymphoid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, FGFR1 or PCM1-JAK2 , 2018, Haematologica.

[2]  Jun Liu,et al.  CSF3R T618I, ASXL1 G942 fs and STAT5B N642H trimutation co‐contribute to a rare chronic neutrophilic leukaemia manifested by rapidly progressive leucocytosis, severe infections, persistent fever and deep venous thrombosis , 2018, British journal of haematology.

[3]  Jisung Park,et al.  Pharmacologic inhibition of STAT5 in acute myeloid leukemia , 2018, Leukemia.

[4]  C. Bock,et al.  STAT5BN642H is a driver mutation for T cell neoplasia , 2017, The Journal of clinical investigation.

[5]  S. Swerdlow.  WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues , 2017 .

[6]  W. Tapper,et al.  Cytogenetically cryptic ZMYM2-FLT3 and DIAPH1-PDGFRB gene fusions in myeloid neoplasms with eosinophilia , 2017, Leukemia.

[7]  A. Reiter,et al.  Myeloid neoplasms with eosinophilia. , 2017, Blood.

[8]  M. Raffeld,et al.  Somatic STAT5b gain-of-function mutations in early onset nonclonal eosinophilia, urticaria, dermatitis, and diarrhea. , 2017, Blood.

[9]  B. Bain,et al.  Guideline for the investigation and management of eosinophilia , 2017, British journal of haematology.

[10]  P. Cin,et al.  Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified , 2016, Modern Pathology.

[11]  A. Tefferi,et al.  Predictors of survival in WHO-defined hypereosinophilic syndrome and idiopathic hypereosinophilia and the role of next-generation sequencing , 2016, Leukemia.

[12]  J. Zehnder,et al.  Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed-phenotype acute leukemia , 2016, Leukemia.

[13]  T. Haferlach,et al.  Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V+ advanced systemic mastocytosis , 2016, Leukemia.

[14]  W. Hofmann,et al.  KIT D816V and JAK2 V617F mutations are seen recurrently in hypereosinophilia of unknown significance , 2015, American journal of hematology.

[15]  P. Campbell,et al.  SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. , 2015, Blood.

[16]  J. Biegel,et al.  Emergence of clonal hematopoiesis in the majority of patients with acquired aplastic anemia. , 2015, Cancer genetics.

[17]  Can Alkan,et al.  Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells , 2015, Nature Communications.

[18]  W. Tapper,et al.  Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes , 2015, Annals of Hematology.

[19]  T. Rausch,et al.  The activating STAT5B N642H mutation is a common abnormality in pediatric T-cell acute lymphoblastic leukemia and confers a higher risk of relapse , 2014, Haematologica.

[20]  K. Elenitoba-Johnson,et al.  Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia. , 2014, Blood.

[21]  R. Aguiar,et al.  Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib. , 2014, Blood.

[22]  M. Stratton,et al.  Clinical and biological implications of driver mutations in myelodysplastic syndromes. , 2013, Blood.

[23]  S. Mustjoki,et al.  Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. , 2013, Blood.

[24]  W. Hofmann,et al.  Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid/lymphoid neoplasms with PDGFR rearrangements in blast phase , 2013, Leukemia.

[25]  T. Haferlach,et al.  High frequencies of SF3B1 and JAK2 mutations in refractory anemia with ring sideroblasts associated with marked thrombocytosis strengthen the assignment to the category of myelodysplastic/myeloproliferative neoplasms , 2013, Haematologica.

[26]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[27]  T. Haferlach,et al.  ICON: Eosinophil Disorders , 2012, The World Allergy Organization journal.

[28]  S. Mustjoki,et al.  Somatic STAT3 mutations in large granular lymphocytic leukemia. , 2012, The New England journal of medicine.

[29]  G. Superti-Furga,et al.  BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia. , 2012, Nature chemical biology.

[30]  L. Hennighausen,et al.  Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice. , 2009, Blood.

[31]  H. Hakonarson,et al.  ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.

[32]  Miyuki Abe,et al.  STAT5 Activation Is Critical for the Transformation Mediated by Myeloproliferative Disorder-associated JAK2 V617F Mutant* , 2009, The Journal of Biological Chemistry.

[33]  Chunaram Choudhary,et al.  Activation mechanisms of STAT5 by oncogenic Flt3-ITD. , 2006, Blood.

[34]  Sandra A. Moore,et al.  Activating alleles of JAK3 in acute megakaryoblastic leukemia. , 2006, Cancer cell.

[35]  J. Trapani,et al.  A functional analysis of the putative polymorphisms A91V and N252S and 22 missense perforin mutations associated with familial hemophagocytic lymphohistiocytosis. , 2005, Blood.

[36]  N. Cross,et al.  Critical Role of STAT5 Activation in Transformation Mediated by ZNF198-FGFR1* , 2004, Journal of Biological Chemistry.

[37]  P. Gascard,et al.  Nucleolar localization of RPS19 protein in normal cells and mislocalization due to mutations in the nucleolar localization signals in 2 Diamond-Blackfan anemia patients: potential insights into pathophysiology. , 2003, Blood.

[38]  J. Lammers,et al.  Signal transducer and activator of transcription 5a (STAT5a) is required for eosinophil differentiation of human cord blood-derived CD34+ cells. , 2003, Blood.

[39]  有好 浩一.  Constitutive activation of STAT5 by a point mutation in the SH2 domain , 2002 .

[40]  I. Day,et al.  An efficient procedure for genotyping single nucleotide polymorphisms. , 2001, Nucleic acids research.

[41]  A. Miyajima,et al.  Constitutive Activation of STAT5 by a Point Mutation in the SH2 Domain* , 2000, The Journal of Biological Chemistry.

[42]  H. Rui,et al.  Stat5a and Stat5b: fraternal twins of signal transduction and transcriptional activation. , 1999, Cytokine & growth factor reviews.

[43]  Can Alkan,et al.  Activating mutations of STAT5B and STAT3 in lymphomas derived from gamma delta-T or NK cells , 2022 .